Mologen AG (Mologen)

Oncology Corporate Profile

HQ Location

Fabeckstr. 30
Berlin, Germany, 14195

Company Description

Mologen AG is a biotechnology company specializing in the research and clinical development of innovative drugs in the fields of oncology and infectious diseases. Their most important developments to date are the DNA immunomodulator MGN1703, which they are currently subjecting to clinical trials in the treatment of advanced colorectal cancer and advanced lung cancer (non-small-cell lung cancer). And their cell-based cancer therapy MGN1601 for the treatment of advanced renal cancer (renal cell carcinoma), which is also a highly promising product, is currently undergoing clinical development as well.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
MGN1703immunomodulatorColorectal cancerII
MGN1703immunomodulatorSmall Cell Lung Cancer (SCLC)II
MGN1601immunomodulatorRenal cell carcinoma (RCC)I
MGN1703immunomodulatorVarious cancer typesI

View additional information on product candidates here »


Recent News Headlines

There are no news items to display